The effect of prostaglandins (PGs) of the A series (A1 and dimethyl PGA2), El, D2, F2~ and PGI2 (prostacyclin) and of inhibitors of PG synthesis (aspirin and indomethacin) on the pathogenicity of vaccinia virus was studied in BALB/c mice. PGs of the A series, D2 and F2~ conferred little or no protection to mice against the lethal effects of vaccinia virus. Mice treated with PGEI showed a dramatic increase in mortality after viral infection. However, when mice were treated with PGI2, their survival was greatly enhanced. Mice treated with aspirin and indomethacin showed a marked increase in mortality. Increased mortality correlated with higher virus yields in target tissues (spleen) and with inhibition of antibody response, whereas the increase in survival correlated with lower virus yields and with normal antibody responses. The significance of our findings is that PGI2 can block the outcome of the disease caused by vaccinia virus whereas other PGs and their inhibitors not only worsen the disease, but may activate and enhance viral infections through immune suppression.
Results of experiments performed in tissue culture cells have suggested that prostaglandins (PGs) may play an important role during viral infection. However, contrasting results have been reported with different virus-cell systems. While PGs of the E and F series had no inhibitory effect on herpes simplex virus (Harbour et al., 1978) , PGE inhibited the production of parainfluenza 3 (Luczak et al., 1975) , polio and encephalomyocarditis viruses (Giron, 1982) . On the other hand, PGs of the A series strongly inhibited Sendai (Santoto et al., 1980) , vesicular stomatitis (Santoro et al., 1983) , and vaccinia virus multiplication (Santoro et al., 1982) . The effect of PGA1 on vaccinia virus was shown to occur at the level of virus gene expression (Benavente et al., 1984) while that on vesicular stomatitis virus is at the glycosylation level (Santoro et al., 1983) . A potent, inhibitory role of PGs on viral infection has also been supported by the results of studies utilizing non-steroidal anti-inflammatory drugs (NSAID) which are inhibitors of PG synthesis. Indeed, during some benign viral diseases, administration of acetylsalicylic acid (ASA) increased the risk of development of Reye's syndrome, a serious childhood illness usually associated with an antecedent episode of infuenza or chickenpox (Starko et al., 1980; Waldman et al., 1982) . Moreover, a dose-related effect of ASA on replication of varicella-zoster virus (Walz-Cicconi & Weller, 1984) and of indomethacin (IMC) on vesicular stomatitis virus (Mukherjee & Simpson, 1984) has been documented in vitro. Because we had previously shown that PGA1 is a potent inhibitor of the replication of vaccinia virus in cultured cells (Santoro et al., 1982; Benavente et al., 1984) , and because live vaccinia virus is a promising biological delivery system for immunizing man and animals against a broad spectrum of disease-causing agents of human and veterinary importance (Moss, 1985) , we have Female mice (30 per group) 8 weeks old were injected i.p. with purified vaccinia virus (WR strain) in 0.3 m! phosphate-buffered saline (PBS). After 1 h, mice were injected (i.p.) with PGs or PG synthesis inhibitors in 0-1 ml. Stocks were prepared as follows: PGs (A1, Di-M-PGAz, E~, Dz and F2~) were dissolved in absolute ethanol (2 mg/ml). PGI2 was dissolved in PBS before use. IMC was dissolved in ethanol (20 mg/ml) and ASA was dissolved in PBS and adjusted to pH 7 with 1 M-NaOH and 1 M-HC1. Injection of the drugs was carried out every 12 h for 10 days. Each drug concentration used per injection is considered to be within the physiological range and was 5 lag for PGs (A~, Di-M-PGA2, El, D2 and F2~), 2.5 lag for PG12, 0.05 mg for IMC and 0.75 mg for ASA. Untreated mice received the equivalent amount (0.1 ml) of control diluent in PBS. The survival rate was evaluated daily for 14 days. In (a), (b) and (J), mice were injected with 5 x 106 p.f.u, of virus, in (c) with 3 x 10 ° p.f.u./mouse, in (d) with 7 x 106 p.f.u./mouse and in (e) with 2 x 106 p.f.u./mouse. Prostaglandins were obtained from Sigma and from Upjohn, Kalamazoo, Mich., U.S.A. Control, solid lines; drug-treated, dashed lines. The variability in mortality between different groups reflects the dosage of virus used.
investigated the effect of PGs and inhibitors of PG synthesis in protecting mice against infection with vaccinia virus. We present here experimental evidence in an animal model system that some PGs are protective against the lethal effects of vaccinia virus replication in vivo but that other PGs increase the mortality of vaccinia virus-infected mice. This increase in mortality is also observed in virus-infected mice treated with inhibitors of PG synthesis.
In the experiments to be described here, all mice (BALB/c; Charles River Breeding Laboratories, Wilmington, Mass., U.S.A.) were inoculated from the same stock of plaquepurified vaccinia virus (strain WR) that had a particle to plaque-forming unit ratio of 30 : 1. The LDso of the virus stock was calculated to be about 5 x 106 p.f.u./mouse. However, in some experiments the virus titre inoculated was slightly lower or higher than 5 × 106 p.f.u./mouse as a result of small changes during virus dilution. This by no means altered the significance of our findings, since the amount of virus inoculated per group in control and drug-treated mice was the same. (c, g, IMC; d, h, ASA) . Mice (ten per group) injected with vaccinia virus and treated with the different drugs (from the same experiment as Fig. 1 ) were bled from a tail vein on days 3 (a to d) and 7 (e to h) after virus inoculation and sera were stored at -70 °C. The antibody response was evaluated by radioimmunoassay. Ultraviolet-irradiated (960 J/m 2) vaccinia virus in carbonate buffer was added to microtitre plates (1 ~tg/well) and after drying 200 p.1 of 1 ~o bovine serum albumin in PBS was added. After 1 h of incubation at 37 °C, wells were washed five times with PBS and 100 ~l of twofold serially diluted serum (1 : 10 to 1 : 160) was added to each well. After 1 h at 37 °C, wells were washed five times with 1 ~o Triton in PBS and 100 gl of I : 2000 diluted goat anti-mouse IgM/IgG (Cappel Laboratories) was added to each well. After 1 h of incubation at 37 °C, wells were washed five times with 1 ~ Triton in PBS and then 100 lal of ~ ~SI-labelled Protein A in PBS was added to each well. Following 1 h of incubation at 37 °C, the wells were washed as above, dried, 200 gl of 0-5 y, SDS, 0-3 M-NaOH was added and the radioactivity was measured in a gamma counter. Control, solid lines; drug-treated, dashed lines. BALB/c mice (100 per experiment) were injected with vaccinia virus by the intraperitoneal (i.p.) route. After virus inoculation, 50 mice were treated with the different agents (i.p.) every 12 h, beginning the treatment at 1 h after virus inoculation, and the treatment was continued for 10 days. Another group of 50 mice received only the control diluent. In the drug-treated, infected mice the following parameters were measured: survival (30 mice per group), dissemination of the virus to target organs (five mice per group selected at random), and host-mediated immune response (10 mice per group selected at random). Fig. 1 shows the kinetics of survival of mice treated with different PGs and with inhibitors of PG synthesis (IMC and aspirin). PGs of the A series conferred little protection to mice against the lethal effects of vaccinia virus. As indicated in Fig. 1, 40 .3~ of mice treated with PGA1 survived for 14 days compared with 50~ for the control group. Similar results were obtained using a stable analogue of PGA, ; when mice were treated with the same doses of Di-M-PGA2 (16,16-dimethyl PGA2 methyl ester) the 14 day survival rate was 26-7~ as compared to 33.3~ for the control group. Mice treated with PGE1 demonstrated a dramatic enhancement in mortality after virus infection; as indicated in Fig. 1 , treated mice had a 14 day survival rate of 13.3~ compared to 73.3~ for the control group (P < 0-001).
When similar experiments were carried out with infected mice treated with PGD 2 or PGF2~ no significant differences were observed in the rate of survival between the treated and untreated groups (data not shown). However, when mice were treated with prostacyclin, PGI2, the survival of infected mice was dramatically enhanced. As indicated in Fig. 1 , under conditions in which all infected mice died within 1 week in the control group, in PGI2-treated mice, in contrast, survival was prolonged and the mortality rate was reduced to 40 ~o (P < 0.001). The effect of the PG synthesis inhibitors, IMC and ASA, on the survival of infected mice was also evaluated. As indicated in Fig. 1 , mice treated with IMC showed a dramatic increase in the rate and time of mortality.While the 14 day survival rate was 96.7~ for the control group, in IMC-treated mice the rate was decreased to 26.7~ (P < 0.001). In a separate experiment in which the survival rate was 50~ for the control group, only 10~ of the mice survived for 14 days after IMC treatment (data not shown). Treatment of mice with aspirin (ASA) also caused an enhancement in mortality; as indicated in Fig. 1 , in mice treated with ASA, the 14 day survival rate was 10~o as compared to 30~o for the relevant control group.
To investigate further whether the differences in survival seen in Fig. 1 are specific for certain PGs, we measured survival in infected mice which received simultaneous treatment of PGs and PG synthesis inhibitors. Our reasoning was that if PGs cause the increase (or decrease) in survival, they would reverse the effect of the PG synthesis inhibitors. The results are shown in Table 1 . As expected, infected mice treated with a combination of PGI2 and IMC showed a significant increase in survival (60~0) as compared to the 10~ survival for those mice which received only IMC (P < 0.025). Treatment of mice with PGD2 or PGF2~ with or without IMC had no significant effect on survival. These findings provide strong evidence that the increase/decrease effect of PGs on survival of mice infected with vaccinia virus is caused by the particular PG.
To further quantify the differences in survival in vaccinia virus-infected mice treated with PGs or with inhibitors of PG synthesis, a direct comparison of virus infectivity in the spleen was carried out. The results are summarized in Table 2 . The levels of virus observed at days 5 and 6 in mice treated with the PGA i were similar to those in the control group. In mice treated with the synthetic PGA analogue Di-M-PGA2, a slight decrease in virus yields was observed as compared to the control group. This small difference from PGA1 might be explained by an Fig.  1) , were selected at random and sacrificed on days 5, 6 and 7; spleens were removed and stored at -70 °C. For virus titration in the different experiments, spleens were weighed, minced and sonicated, the tissue suspension was serially diluted and virus infectivity was quantified by plaque formation on African green monkey kidney (BSC-40) cells by the standard agar overlay technique (Santoro et al., 1982) . Duplicate 60 mm tissue culture dishes were used for each virus dilution. The number of mice used per group was five, except in the Di-M-PGA2 group, which was ten. enhanced metabolic stability of the long-acting analogue. In mice treated with PGE, the virus yields were similar to those in the control group on day 5 after virus inoculation. However, by day 7 the virus yields were higher in PGEl-treated mice. The reduction of virus titre at day 7 is most likely the result of host cell-mediated immune responses. In contrast, in mice treated with PGI2, a significant reduction in virus yield was observed after 5 days. The virus yields were also measured in the spleens of mice treated with inhibitors of PG synthesis. In mice treated with IMC or ASA, the virus concentrations on day 5 were similar to those in the control group but were higher by days 6 or 7. This result suggests that NSAID enhance the persistence of vaccinia virus in target organs.
Since the enduring immunity which results after infection of mice with vaccinia virus probably reflects humoral immune responses, it was of interest to determine whether the antibody responses of drug-treated mice were altered by PGs and PG synthesis inhibitors. This was evaluated by radioimmunoassay measurements of specific proteins in blood samples collected at 3 and 7 days after virus infection from mice selected at random. Antibody-producing cells at 3 days (early) after virus infection consist mostly of the IgM-secreting class while at 7 days (late) after infection, the cells are predominantly of the IgG-secreting class. The results of the immunoassay studies are presented in Fig. 2 . In infected mice treated with PGA1, no significant differences were observed in the early or late antibody responses as compared to those in control mice. However, in infected mice treated with PGE1 a marked decrease in antibody response (IgM and IgG) was observed. No difference in antibody response was observed in PGl2-treated as compared to untreated, infected mice (data not shown). Finally, in infected mice treated with inhibitors of PG synthesis, the early antibody response (IgM) was the same as in the control group, while the late antibody response (IgG) was significantly reduced.
The present series of studies, based on the interaction of vaccinia virus with PGs and NSAID in a mouse model, demonstrated four major findings: (i) that PGI2 markedly protects mice against the lethal effects of vaccinia virus, (ii) that PGE1 dramatically increases the mortality of infected mice, (iii) that PGA 1 has no significant protective action against vaceinia virus replication in contrast to its protective effect in vitro and (iv) that NSAID such as IMC and ASA increase the mortality and virus persistence in infected mice.
The lack of PGAl-induced inhibition of vaccinia virus replication in vivo might be related to the concentrations used in vitro (Santoro et al., 1982) which exceed the maximal concentration achievable in vivo. Alternatively, there might be more degradation in vivo. This latter possibility might explain why the more stable PGA2 synthetic analogue had some effect on virus multiplication in the spleen. The dramatic effect of PGE1, increasing the mortality of mice infected with vaccinia virus, might be explained by the effect of PGE on the immune system. Indeed, it is known that PGs of the E series inhibit antibody production (Braun & Ishizuka, 1971 ; Morito et al., 1980; Ceuppens & Goodwin, 1982) , inhibit the expression of Ia antigens on macrophages (Snyder et al., 1982) , and depress many functions of T lymphocytes in vitro, such as mitogen responsiveness (Goodwin et al., 1979a) , E-rosette formation (Erten et al., 1980) and lymphokine production (Gordon et al., 1976; Rappaport & Dodge, 1982) . The inhibitory effect of PGE on the humoral immune response could be due to a direct action on B cells or to effects on helper and suppressor T cells (Goodwin & Ceuppens, 1983) . These effects on the immune system are consistent with our observed inhibition of antibody response in mice infected with vaccinia virus and treated with PGE1, as well as with the high mortality rate and the increase of virus yields in target organs.
The finding that PGI2 protects mice against vaccinia virus infection is of interest. PGI 2, the most potent natural inhibitor of platelet aggregation and a vasodilator, appears to exert its influence by regulating production of cyclic AMP. However, the ease with which PGI2 is hydrolyzed (Stehle, 1982) suggests either that PGI2 acts on target cells (i.e. macrophages) immediately after i.p. inoculation or that a metabolic product acts as an inhibitor of vaccinia virus infection.
It is of importance that two common non-steroidal anti-inflammatory drugs, such as IMC and ASA, increased the severity of vaccinia virus infection in mice. At the doses used in our experiment, IMC induced a greater increase in mortality than ASA. Both of these drugs impaired the immune system, as measured by antibody production (Fig. 2) . Since it has been well documented that PGs have important immunoregulatory properties, it is probable that the immunological effect of these anti-inflammatory drugs is due to their inhibition of PG synthesis. The immunosuppressive action of NSAID in our experiments contrasts with the results of other in vivo studies which reported enhanced humoral responses (Kuzimiera et al., 1977; Goodwin et al., 1978 b ) although neither of these previous studies were carried out in virus-infected animals. Furthermore, only IgM-forming cells were evaluated (Goodwin et al., 1978b) and as reported here, the IgM levels were unaffected by NSAID while IgG production was significantly depressed. While it is probable that alterations of the immune system by NSAID contribute to enhancement of the lethal effects of vaccinia virus in immunocompromised mice, it is likely that other mechanism(s) may also be involved. Indeed, we have shown that PGI2 has an important protective action against vaccinia virus infection and both IMC and ASA inhibit PGIz synthesis in vitro and in vivo (Marcus, 1977; Burch et al., 1978; Jaffe & Weksler, 1979; Masotti et al., 1979) . Thus, inhibition of PGI2 synthesis by NSAID might enhance the pathogenicity of vaccinia virus and, if so, PGI2 might play an important role against virus infections, at least for vaccinia virus.
The significance of our findings is that PGI2 can block the outcome of the disease caused by vaccinia virus but that the use of PGE1 and of inhibitors of PG synthesis in vivo worsens the disease. Because there is known to be a good correlation between Reye's syndrome and aspirin intake (Halpin et al., 1982) these drugs might, in turn, activate and enhance latent viral infections. Our results might also be relevant to vaccination and to interferon therapy. Live vaccinia virus carrying genes of human and veterinary importance might eventually be used as a polyvalent vaccine. Our findings suggest that vaccines treated with some PGs and NSAID might show increased spread of the vaccinia infection. Since interferon enhances the production of FGI2 by vascular endothelial cells (Eldor et at., 1984) , it could be hypothesized that interferon and PGI2 act synergistically against virus infections by preventing virus multiplication in infected cells and by preventing virus-induced endothelial damage which, in turn, could contribute to limiting the spread of the virus to other tissues.
